Review



neural crest stem cell microbeads  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Miltenyi Biotec neural crest stem cell microbeads
    Neural Crest Stem Cell Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 22 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/neural crest stem cell microbeads/product/Miltenyi Biotec
    Average 95 stars, based on 22 article reviews
    neural crest stem cell microbeads - by Bioz Stars, 2026-02
    95/100 stars

    Images



    Similar Products

    95
    Miltenyi Biotec neural crest stem cell microbeads
    Neural Crest Stem Cell Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/neural crest stem cell microbeads/product/Miltenyi Biotec
    Average 95 stars, based on 1 article reviews
    neural crest stem cell microbeads - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec cd8 microbeads
    PDOTS surface marker staining (A) Scheme showing the steps for surface marker staining of PDOTS “on chip”. (B) Surface markers staining of melanoma PDOTS. The left image is an overlay of the indicated markers. White arrows denote CD38 + <t>CD8</t> + T cells inside a tumor spheroid.
    Cd8 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8 microbeads/product/Miltenyi Biotec
    Average 99 stars, based on 1 article reviews
    cd8 microbeads - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec indirect cd133 microbeads
    PDOTS surface marker staining (A) Scheme showing the steps for surface marker staining of PDOTS “on chip”. (B) Surface markers staining of melanoma PDOTS. The left image is an overlay of the indicated markers. White arrows denote CD38 + <t>CD8</t> + T cells inside a tumor spheroid.
    Indirect Cd133 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/indirect cd133 microbeads/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    indirect cd133 microbeads - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec human cd34 microbeads kit
    Generation of Allo CAR70-NKT cells from HSPCs using a clinically guided culture method (A and B) Schematics showing the generation of Allo CAR70-NKT cells (A) and the design of Lenti/iNKT-CAR70-IL-15 lentivector (B). (C) FACS detection of NKT TCR expression in lentivector-transduced <t>CD34</t> + HSPCs. (D) Quantification of (C) (n = 5; n indicates different cord blood donors). (E) FACS monitoring of the generation of Allo CAR70-NKT cells during the 6-week culture. (F) Percentage of Allo CAR70-NKT cells in total live cells during the 6-week culture (n = 5; n indicates different cord blood donors). (G) Yield of Allo CAR70-NKT cells (n = 5; n indicates different cord blood donors). (H) CAR70 expression on Allo CAR70-NKT cells (n = 5; n indicates different cord blood donors). (I) ELISA measurements of IL-15 production by Allo CAR70-NKT cells with or without αGC stimulation (n = 4). (J) CD4/CD8 subpopulations of Allo CAR70-NKT cells. Data generated from 5 cord blood donors are shown. SP, single-positive; DP, double-positive; DN, double-negative. (K–M) Antigen responses of Allo CAR70-NKT cells. Allo CAR70-NKT cells were stimulated with/without αGC-loaded PBMCs for 1 week. (K) Experimental design. (L) Growth curve of Allo CAR70-NKT cells (n = 4). (M) ELISA measurements of effector cytokine levels in the culture supernatants collected on day 5 (n = 4). Representative of over 5 experiments. Data are presented as the mean ± SEM. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 by Student’s t test (I and M).
    Human Cd34 Microbeads Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cd34 microbeads kit/product/Miltenyi Biotec
    Average 99 stars, based on 1 article reviews
    human cd34 microbeads kit - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec human anti nkt microbeads
    Generation of Allo CAR70-NKT cells from HSPCs using a clinically guided culture method (A and B) Schematics showing the generation of Allo CAR70-NKT cells (A) and the design of Lenti/iNKT-CAR70-IL-15 lentivector (B). (C) FACS detection of NKT TCR expression in lentivector-transduced <t>CD34</t> + HSPCs. (D) Quantification of (C) (n = 5; n indicates different cord blood donors). (E) FACS monitoring of the generation of Allo CAR70-NKT cells during the 6-week culture. (F) Percentage of Allo CAR70-NKT cells in total live cells during the 6-week culture (n = 5; n indicates different cord blood donors). (G) Yield of Allo CAR70-NKT cells (n = 5; n indicates different cord blood donors). (H) CAR70 expression on Allo CAR70-NKT cells (n = 5; n indicates different cord blood donors). (I) ELISA measurements of IL-15 production by Allo CAR70-NKT cells with or without αGC stimulation (n = 4). (J) CD4/CD8 subpopulations of Allo CAR70-NKT cells. Data generated from 5 cord blood donors are shown. SP, single-positive; DP, double-positive; DN, double-negative. (K–M) Antigen responses of Allo CAR70-NKT cells. Allo CAR70-NKT cells were stimulated with/without αGC-loaded PBMCs for 1 week. (K) Experimental design. (L) Growth curve of Allo CAR70-NKT cells (n = 4). (M) ELISA measurements of effector cytokine levels in the culture supernatants collected on day 5 (n = 4). Representative of over 5 experiments. Data are presented as the mean ± SEM. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 by Student’s t test (I and M).
    Human Anti Nkt Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human anti nkt microbeads/product/Miltenyi Biotec
    Average 95 stars, based on 1 article reviews
    human anti nkt microbeads - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    98
    Miltenyi Biotec cd19 beads
    NKG2A-edited CAR NK cells eliminate <t>CD19-negative</t> target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 <t>CD19-positive</t> 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
    Cd19 Beads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd19 beads/product/Miltenyi Biotec
    Average 98 stars, based on 1 article reviews
    cd19 beads - by Bioz Stars, 2026-02
    98/100 stars
      Buy from Supplier

    98
    Miltenyi Biotec cd19 cells
    NKG2A-edited CAR NK cells eliminate <t>CD19-negative</t> target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 <t>CD19-positive</t> 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
    Cd19 Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd19 cells/product/Miltenyi Biotec
    Average 98 stars, based on 1 article reviews
    cd19 cells - by Bioz Stars, 2026-02
    98/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec anti biotin microbeads
    NKG2A-edited CAR NK cells eliminate <t>CD19-negative</t> target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 <t>CD19-positive</t> 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
    Anti Biotin Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti biotin microbeads/product/Miltenyi Biotec
    Average 99 stars, based on 1 article reviews
    anti biotin microbeads - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec magnetic anti mouse cd43 microbeads
    NKG2A-edited CAR NK cells eliminate <t>CD19-negative</t> target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 <t>CD19-positive</t> 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
    Magnetic Anti Mouse Cd43 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/magnetic anti mouse cd43 microbeads/product/Miltenyi Biotec
    Average 96 stars, based on 1 article reviews
    magnetic anti mouse cd43 microbeads - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd43 ly 48 microbeads
    Description and characterization of different aspects of the sgRNA screening system. (A) Flow cytometric analysis of mCherry expression in B cells at 2 and 3 days after infection with a control mCherry-LV. The cells were cultured on OP9 cells with sBAFF (right). The frequencies of mCherry + B cells are shown as mean values with SEM and were analyzed by one-way ANOVA with Tukey’s multiple comparisons test; ***P < 0.001; ****P < 0.0001. (B) Flow cytometric analysis of dividing and nondividing mCherry + B cells after 3 days in culture on OP9 cells with sBAFF. Mature <t>CD43</t> – B cells were incubated with CellTrace Violet prior to infection with a control mCherry-LV and were subsequently cultured for 3 days. The frequencies of mCherry + B cells among the dividing and nondividing B cell population are shown as mean values with SEM and were analyzed by the unpaired t test; ***P < 0.001. (C) Immunofluorescence staining of spleen sections from recipient mice at 5 and 7 days after immunization with NP-KLH/alum. LV infection and B cell transfer were performed as described in D. Spleen sections were stained with antibodies against IgD (green), mCherry (red), TCRβ (blue), and IRF4 (white). A nonimmunized mouse, which did not receive transduced mCherry + B cells, was used as a control. The scale bar represents 100 μm. (D) Time course of plasmablast formation upon immunization with NP-Ficoll. Naïve B cells isolated from the donor mice were transduced with LV particles expressing a neutral control sgRNA (sg. Chr1 ) and the mCherry reporter protein. After infection, B cells were cultured in vitro for 3 days in the presence of stromal OP9 cells and sBAFF. Transduced mCherry + B cells were isolated and transferred to recipient mice, which were immunized 16 h later with NP-Ficoll in PBS. Flow cytometric analysis of splenocytes from recipient mice at day 3, 5, and 7 after immunization (left) revealed the percentages of mCherry + B cells in total splenocytes and mCherry + plasmablasts (TACI + CD138 + ) within the mCherry + cells, as shown in the bar graphs (right). Absolute numbers of the mCherry + B cells and mCherry + plasmablasts in the spleen are also indicated (far right). Statistical data are shown as mean values with SEM and were analyzed by the Welch ANOVA with the Brown–Forsythe test; *P < 0.05; **P < 0.01; ****P < 0.0001. Each dot represents one mouse. AF, autofluorescence measured in the BV605 channel. (E) Scheme describing the steps taken for the selection of the 379 genes to be studied in the in vivo CRISPR/Cas9 screening experiments. The data shown in A, B, and D are based on two independent experiments. Each dot corresponds to one mouse.
    Cd43 Ly 48 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd43 ly 48 microbeads/product/Miltenyi Biotec
    Average 96 stars, based on 1 article reviews
    cd43 ly 48 microbeads - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    Image Search Results


    PDOTS surface marker staining (A) Scheme showing the steps for surface marker staining of PDOTS “on chip”. (B) Surface markers staining of melanoma PDOTS. The left image is an overlay of the indicated markers. White arrows denote CD38 + CD8 + T cells inside a tumor spheroid.

    Journal: STAR Protocols

    Article Title: Protocol for the preparation and analysis of patient-derived organotypic tumor spheroids

    doi: 10.1016/j.xpro.2025.104286

    Figure Lengend Snippet: PDOTS surface marker staining (A) Scheme showing the steps for surface marker staining of PDOTS “on chip”. (B) Surface markers staining of melanoma PDOTS. The left image is an overlay of the indicated markers. White arrows denote CD38 + CD8 + T cells inside a tumor spheroid.

    Article Snippet: CD8 MicroBeads , Miltenyi , Cat#130-045-201.

    Techniques: Marker, Staining

    Generation of Allo CAR70-NKT cells from HSPCs using a clinically guided culture method (A and B) Schematics showing the generation of Allo CAR70-NKT cells (A) and the design of Lenti/iNKT-CAR70-IL-15 lentivector (B). (C) FACS detection of NKT TCR expression in lentivector-transduced CD34 + HSPCs. (D) Quantification of (C) (n = 5; n indicates different cord blood donors). (E) FACS monitoring of the generation of Allo CAR70-NKT cells during the 6-week culture. (F) Percentage of Allo CAR70-NKT cells in total live cells during the 6-week culture (n = 5; n indicates different cord blood donors). (G) Yield of Allo CAR70-NKT cells (n = 5; n indicates different cord blood donors). (H) CAR70 expression on Allo CAR70-NKT cells (n = 5; n indicates different cord blood donors). (I) ELISA measurements of IL-15 production by Allo CAR70-NKT cells with or without αGC stimulation (n = 4). (J) CD4/CD8 subpopulations of Allo CAR70-NKT cells. Data generated from 5 cord blood donors are shown. SP, single-positive; DP, double-positive; DN, double-negative. (K–M) Antigen responses of Allo CAR70-NKT cells. Allo CAR70-NKT cells were stimulated with/without αGC-loaded PBMCs for 1 week. (K) Experimental design. (L) Growth curve of Allo CAR70-NKT cells (n = 4). (M) ELISA measurements of effector cytokine levels in the culture supernatants collected on day 5 (n = 4). Representative of over 5 experiments. Data are presented as the mean ± SEM. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 by Student’s t test (I and M).

    Journal: STAR Protocols

    Article Title: Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma

    doi: 10.1016/j.xpro.2025.104340

    Figure Lengend Snippet: Generation of Allo CAR70-NKT cells from HSPCs using a clinically guided culture method (A and B) Schematics showing the generation of Allo CAR70-NKT cells (A) and the design of Lenti/iNKT-CAR70-IL-15 lentivector (B). (C) FACS detection of NKT TCR expression in lentivector-transduced CD34 + HSPCs. (D) Quantification of (C) (n = 5; n indicates different cord blood donors). (E) FACS monitoring of the generation of Allo CAR70-NKT cells during the 6-week culture. (F) Percentage of Allo CAR70-NKT cells in total live cells during the 6-week culture (n = 5; n indicates different cord blood donors). (G) Yield of Allo CAR70-NKT cells (n = 5; n indicates different cord blood donors). (H) CAR70 expression on Allo CAR70-NKT cells (n = 5; n indicates different cord blood donors). (I) ELISA measurements of IL-15 production by Allo CAR70-NKT cells with or without αGC stimulation (n = 4). (J) CD4/CD8 subpopulations of Allo CAR70-NKT cells. Data generated from 5 cord blood donors are shown. SP, single-positive; DP, double-positive; DN, double-negative. (K–M) Antigen responses of Allo CAR70-NKT cells. Allo CAR70-NKT cells were stimulated with/without αGC-loaded PBMCs for 1 week. (K) Experimental design. (L) Growth curve of Allo CAR70-NKT cells (n = 4). (M) ELISA measurements of effector cytokine levels in the culture supernatants collected on day 5 (n = 4). Representative of over 5 experiments. Data are presented as the mean ± SEM. ns, not significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 by Student’s t test (I and M).

    Article Snippet: Human CD34 MicroBeads Kit , Miltenyi Biotec , CAT#130-046-703.

    Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Generated

    NKG2A-edited CAR NK cells eliminate CD19-negative target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 CD19-positive 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Journal: Molecular Therapy Oncology

    Article Title: Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells

    doi: 10.1016/j.omton.2026.201126

    Figure Lengend Snippet: NKG2A-edited CAR NK cells eliminate CD19-negative target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 CD19-positive 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Article Snippet: EBV-transformed LCLs from allogeneic human fetal liver tissue were generated by isolating CD19 + cells by magnetic-activated cell sorting with CD19 beads (Miltenyi, Cat. 130-050-301) and then infected with EBV B95-8, produced as previously described at a multiplicity of infection (MOI) of 0.05–0.15.

    Techniques: Lysis, Cell Culture, Labeling, Generated, Expressing, Flow Cytometry, Co-Culture Assay

    Increased cytotoxicity of NKG2A-edited CAR NK cells against CD19-negative BCP-ALL PDX (A) CD19 and (B) HLA-E expression of BCP-ALL PDX by flow cytometry. (C) Specific lysis of PDX1 and PDX2 after co-culture with control NK cells (NK mock) or CAR NK cells (CAR mock). Co-culture at E:T ratio 5:1 for 4 h. (D) Specific lysis of PDX1 after 4 h co-culture at 1:1 E:T ratio. (E) Data from (D) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (F–H) Specific lysis of PDX2 after 20 h co-culture at 5:1 E:T ratio with NK (F) or CAR NK (G) cells. (H) Data from (G) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (C) n = 3 (individual donors), paired t test. (D–G) n = 3 (individual donors), repeated measures one-way ANOVA. Engineered NK cells shown in this figure were generated from bulk NK cells (not NKG2A + NK cells) as the starting population. ∗ p < 0.05.

    Journal: Molecular Therapy Oncology

    Article Title: Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells

    doi: 10.1016/j.omton.2026.201126

    Figure Lengend Snippet: Increased cytotoxicity of NKG2A-edited CAR NK cells against CD19-negative BCP-ALL PDX (A) CD19 and (B) HLA-E expression of BCP-ALL PDX by flow cytometry. (C) Specific lysis of PDX1 and PDX2 after co-culture with control NK cells (NK mock) or CAR NK cells (CAR mock). Co-culture at E:T ratio 5:1 for 4 h. (D) Specific lysis of PDX1 after 4 h co-culture at 1:1 E:T ratio. (E) Data from (D) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (F–H) Specific lysis of PDX2 after 20 h co-culture at 5:1 E:T ratio with NK (F) or CAR NK (G) cells. (H) Data from (G) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (C) n = 3 (individual donors), paired t test. (D–G) n = 3 (individual donors), repeated measures one-way ANOVA. Engineered NK cells shown in this figure were generated from bulk NK cells (not NKG2A + NK cells) as the starting population. ∗ p < 0.05.

    Article Snippet: EBV-transformed LCLs from allogeneic human fetal liver tissue were generated by isolating CD19 + cells by magnetic-activated cell sorting with CD19 beads (Miltenyi, Cat. 130-050-301) and then infected with EBV B95-8, produced as previously described at a multiplicity of infection (MOI) of 0.05–0.15.

    Techniques: Expressing, Flow Cytometry, Lysis, Co-Culture Assay, Control, Generated

    NKG2A-edited CAR NK cells eliminate CD19-negative target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 CD19-positive 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Journal: Molecular Therapy Oncology

    Article Title: Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells

    doi: 10.1016/j.omton.2026.201126

    Figure Lengend Snippet: NKG2A-edited CAR NK cells eliminate CD19-negative target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 CD19-positive 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Article Snippet: EBV-transformed LCLs from allogeneic human fetal liver tissue were generated by isolating CD19 + cells by magnetic-activated cell sorting with CD19 beads (Miltenyi, Cat. 130-050-301) and then infected with EBV B95-8, produced as previously described at a multiplicity of infection (MOI) of 0.05–0.15.

    Techniques: Lysis, Cell Culture, Labeling, Generated, Expressing, Flow Cytometry, Co-Culture Assay

    Increased cytotoxicity of NKG2A-edited CAR NK cells against CD19-negative BCP-ALL PDX (A) CD19 and (B) HLA-E expression of BCP-ALL PDX by flow cytometry. (C) Specific lysis of PDX1 and PDX2 after co-culture with control NK cells (NK mock) or CAR NK cells (CAR mock). Co-culture at E:T ratio 5:1 for 4 h. (D) Specific lysis of PDX1 after 4 h co-culture at 1:1 E:T ratio. (E) Data from (D) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (F–H) Specific lysis of PDX2 after 20 h co-culture at 5:1 E:T ratio with NK (F) or CAR NK (G) cells. (H) Data from (G) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (C) n = 3 (individual donors), paired t test. (D–G) n = 3 (individual donors), repeated measures one-way ANOVA. Engineered NK cells shown in this figure were generated from bulk NK cells (not NKG2A + NK cells) as the starting population. ∗ p < 0.05.

    Journal: Molecular Therapy Oncology

    Article Title: Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells

    doi: 10.1016/j.omton.2026.201126

    Figure Lengend Snippet: Increased cytotoxicity of NKG2A-edited CAR NK cells against CD19-negative BCP-ALL PDX (A) CD19 and (B) HLA-E expression of BCP-ALL PDX by flow cytometry. (C) Specific lysis of PDX1 and PDX2 after co-culture with control NK cells (NK mock) or CAR NK cells (CAR mock). Co-culture at E:T ratio 5:1 for 4 h. (D) Specific lysis of PDX1 after 4 h co-culture at 1:1 E:T ratio. (E) Data from (D) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (F–H) Specific lysis of PDX2 after 20 h co-culture at 5:1 E:T ratio with NK (F) or CAR NK (G) cells. (H) Data from (G) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (C) n = 3 (individual donors), paired t test. (D–G) n = 3 (individual donors), repeated measures one-way ANOVA. Engineered NK cells shown in this figure were generated from bulk NK cells (not NKG2A + NK cells) as the starting population. ∗ p < 0.05.

    Article Snippet: EBV-transformed LCLs from allogeneic human fetal liver tissue were generated by isolating CD19 + cells by magnetic-activated cell sorting with CD19 beads (Miltenyi, Cat. 130-050-301) and then infected with EBV B95-8, produced as previously described at a multiplicity of infection (MOI) of 0.05–0.15.

    Techniques: Expressing, Flow Cytometry, Lysis, Co-Culture Assay, Control, Generated

    Description and characterization of different aspects of the sgRNA screening system. (A) Flow cytometric analysis of mCherry expression in B cells at 2 and 3 days after infection with a control mCherry-LV. The cells were cultured on OP9 cells with sBAFF (right). The frequencies of mCherry + B cells are shown as mean values with SEM and were analyzed by one-way ANOVA with Tukey’s multiple comparisons test; ***P < 0.001; ****P < 0.0001. (B) Flow cytometric analysis of dividing and nondividing mCherry + B cells after 3 days in culture on OP9 cells with sBAFF. Mature CD43 – B cells were incubated with CellTrace Violet prior to infection with a control mCherry-LV and were subsequently cultured for 3 days. The frequencies of mCherry + B cells among the dividing and nondividing B cell population are shown as mean values with SEM and were analyzed by the unpaired t test; ***P < 0.001. (C) Immunofluorescence staining of spleen sections from recipient mice at 5 and 7 days after immunization with NP-KLH/alum. LV infection and B cell transfer were performed as described in D. Spleen sections were stained with antibodies against IgD (green), mCherry (red), TCRβ (blue), and IRF4 (white). A nonimmunized mouse, which did not receive transduced mCherry + B cells, was used as a control. The scale bar represents 100 μm. (D) Time course of plasmablast formation upon immunization with NP-Ficoll. Naïve B cells isolated from the donor mice were transduced with LV particles expressing a neutral control sgRNA (sg. Chr1 ) and the mCherry reporter protein. After infection, B cells were cultured in vitro for 3 days in the presence of stromal OP9 cells and sBAFF. Transduced mCherry + B cells were isolated and transferred to recipient mice, which were immunized 16 h later with NP-Ficoll in PBS. Flow cytometric analysis of splenocytes from recipient mice at day 3, 5, and 7 after immunization (left) revealed the percentages of mCherry + B cells in total splenocytes and mCherry + plasmablasts (TACI + CD138 + ) within the mCherry + cells, as shown in the bar graphs (right). Absolute numbers of the mCherry + B cells and mCherry + plasmablasts in the spleen are also indicated (far right). Statistical data are shown as mean values with SEM and were analyzed by the Welch ANOVA with the Brown–Forsythe test; *P < 0.05; **P < 0.01; ****P < 0.0001. Each dot represents one mouse. AF, autofluorescence measured in the BV605 channel. (E) Scheme describing the steps taken for the selection of the 379 genes to be studied in the in vivo CRISPR/Cas9 screening experiments. The data shown in A, B, and D are based on two independent experiments. Each dot corresponds to one mouse.

    Journal: The Journal of Experimental Medicine

    Article Title: In vivo CRISPR/Cas9 screens identify new regulators of B cell activation and plasma cell differentiation

    doi: 10.1084/jem.20250594

    Figure Lengend Snippet: Description and characterization of different aspects of the sgRNA screening system. (A) Flow cytometric analysis of mCherry expression in B cells at 2 and 3 days after infection with a control mCherry-LV. The cells were cultured on OP9 cells with sBAFF (right). The frequencies of mCherry + B cells are shown as mean values with SEM and were analyzed by one-way ANOVA with Tukey’s multiple comparisons test; ***P < 0.001; ****P < 0.0001. (B) Flow cytometric analysis of dividing and nondividing mCherry + B cells after 3 days in culture on OP9 cells with sBAFF. Mature CD43 – B cells were incubated with CellTrace Violet prior to infection with a control mCherry-LV and were subsequently cultured for 3 days. The frequencies of mCherry + B cells among the dividing and nondividing B cell population are shown as mean values with SEM and were analyzed by the unpaired t test; ***P < 0.001. (C) Immunofluorescence staining of spleen sections from recipient mice at 5 and 7 days after immunization with NP-KLH/alum. LV infection and B cell transfer were performed as described in D. Spleen sections were stained with antibodies against IgD (green), mCherry (red), TCRβ (blue), and IRF4 (white). A nonimmunized mouse, which did not receive transduced mCherry + B cells, was used as a control. The scale bar represents 100 μm. (D) Time course of plasmablast formation upon immunization with NP-Ficoll. Naïve B cells isolated from the donor mice were transduced with LV particles expressing a neutral control sgRNA (sg. Chr1 ) and the mCherry reporter protein. After infection, B cells were cultured in vitro for 3 days in the presence of stromal OP9 cells and sBAFF. Transduced mCherry + B cells were isolated and transferred to recipient mice, which were immunized 16 h later with NP-Ficoll in PBS. Flow cytometric analysis of splenocytes from recipient mice at day 3, 5, and 7 after immunization (left) revealed the percentages of mCherry + B cells in total splenocytes and mCherry + plasmablasts (TACI + CD138 + ) within the mCherry + cells, as shown in the bar graphs (right). Absolute numbers of the mCherry + B cells and mCherry + plasmablasts in the spleen are also indicated (far right). Statistical data are shown as mean values with SEM and were analyzed by the Welch ANOVA with the Brown–Forsythe test; *P < 0.05; **P < 0.01; ****P < 0.0001. Each dot represents one mouse. AF, autofluorescence measured in the BV605 channel. (E) Scheme describing the steps taken for the selection of the 379 genes to be studied in the in vivo CRISPR/Cas9 screening experiments. The data shown in A, B, and D are based on two independent experiments. Each dot corresponds to one mouse.

    Article Snippet: CD43 – B cells were enriched from the spleen or lymph nodes of mice by immunomagnetic depletion of non-B cells using CD43 (Ly-48) MicroBeads (Miltenyi Biotec).

    Techniques: Expressing, Infection, Control, Cell Culture, Incubation, Immunofluorescence, Staining, Isolation, Transduction, In Vitro, Selection, In Vivo, CRISPR

    Indel sequencing data, identification of GC B cell– and PB-specific sgRNA hits, and sgRNA representation at different stages of the screening experiments. (A and B) Indel sequencing. Mature CD43 – B cells were infected with the indicated sgRNA mCherry-LVs, cultured for 3 days on OP9 cells with sBAFF, and then stimulated with CpG, IL-4, and IL-5 for another 3 days, followed by flow cytometric sorting of the mCherry + B cells and DNA preparation. Indel sequencing was performed by PCR amplification and sequencing of a DNA fragment spanning the sgRNA break site, followed by TIDE analysis . (A) Percentages of indels are indicated relative to the break site of sg. Cd44 (position 0, black), demonstrating that the percentage of indels is 88% for the sg. Cd44 . (B) Percentages of indels are shown for the indicated sgRNAs, as determined by the indel sequencing and TIDE analysis. (C) Identification of GC B cell–specific and PB-specific positive and negative regulators, as determined by CRISPR/Cas9 screening experiments at day 7 after NP-KLH immunization. The log 2 FC plot (left) indicates the sgRNA hits that were determined by a more than twofold change in sgRNA abundance in GC B cells and PBs (corresponding to ). The genes corresponding to the GC B cell–specific and PB-specific sgRNA hits are shown (right), and their fold changes and P values are indicated in . The common positive regulators are shown in , as being significant in both cell types, while the PB-specific positive regulators are indicated as being nonsignificant in the GC B cell analysis . (D) sgRNA representation at different stages of the TD and TI screening experiments. Flow cytometric analysis was used to determine the number of sorted mCherry + B cells at the start, the splenic mCherry + B cells at day 3 after B cell transfer ( [TD] and S1D [TI]), and the splenic mCherry + PBs, GC B cells, and memory B cells at day 7 ( [TD] and S4D [TI]). As the screening library contained 882 sgRNAs, the number of identified B cells was divided by 882 to determine how many cells contained one specific sgRNA (cells/sgRNA) under the assumption that each cell was only infected by one sgRNA virus (MOI = 1). (E) Schematic representation of the LV vectors used in this study. LVs containing the PGK-mCherry or EF1a-mCherry gene were used for establishing and testing of the in vivo CRISPR/Cas9 screening system. The sgRNA library was cloned in a LV vector containing the EF1as-mCherry gene. The validation experiments were performed with LVs containing the EF1as-mCherry or EF1as-mAmetrine gene. 5′LTR, 5′ long terminal repeat; Ψ, psi packaging signal; RRE, Rev response element; cPPT, central polypurine tract; PBS, primer binding site for DNA sequencing library preparation; hU6, human U6 promoter; hPGK, human phosphoglycerate kinase promoter; hEF1a, human elongation factor 1a promoter; hEF1as, human elongation factor 1a short promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element; 3′LTR (SIN), 3′ long terminal repeat (self-inactivating); FC, fold change; PBs, plasmablasts.

    Journal: The Journal of Experimental Medicine

    Article Title: In vivo CRISPR/Cas9 screens identify new regulators of B cell activation and plasma cell differentiation

    doi: 10.1084/jem.20250594

    Figure Lengend Snippet: Indel sequencing data, identification of GC B cell– and PB-specific sgRNA hits, and sgRNA representation at different stages of the screening experiments. (A and B) Indel sequencing. Mature CD43 – B cells were infected with the indicated sgRNA mCherry-LVs, cultured for 3 days on OP9 cells with sBAFF, and then stimulated with CpG, IL-4, and IL-5 for another 3 days, followed by flow cytometric sorting of the mCherry + B cells and DNA preparation. Indel sequencing was performed by PCR amplification and sequencing of a DNA fragment spanning the sgRNA break site, followed by TIDE analysis . (A) Percentages of indels are indicated relative to the break site of sg. Cd44 (position 0, black), demonstrating that the percentage of indels is 88% for the sg. Cd44 . (B) Percentages of indels are shown for the indicated sgRNAs, as determined by the indel sequencing and TIDE analysis. (C) Identification of GC B cell–specific and PB-specific positive and negative regulators, as determined by CRISPR/Cas9 screening experiments at day 7 after NP-KLH immunization. The log 2 FC plot (left) indicates the sgRNA hits that were determined by a more than twofold change in sgRNA abundance in GC B cells and PBs (corresponding to ). The genes corresponding to the GC B cell–specific and PB-specific sgRNA hits are shown (right), and their fold changes and P values are indicated in . The common positive regulators are shown in , as being significant in both cell types, while the PB-specific positive regulators are indicated as being nonsignificant in the GC B cell analysis . (D) sgRNA representation at different stages of the TD and TI screening experiments. Flow cytometric analysis was used to determine the number of sorted mCherry + B cells at the start, the splenic mCherry + B cells at day 3 after B cell transfer ( [TD] and S1D [TI]), and the splenic mCherry + PBs, GC B cells, and memory B cells at day 7 ( [TD] and S4D [TI]). As the screening library contained 882 sgRNAs, the number of identified B cells was divided by 882 to determine how many cells contained one specific sgRNA (cells/sgRNA) under the assumption that each cell was only infected by one sgRNA virus (MOI = 1). (E) Schematic representation of the LV vectors used in this study. LVs containing the PGK-mCherry or EF1a-mCherry gene were used for establishing and testing of the in vivo CRISPR/Cas9 screening system. The sgRNA library was cloned in a LV vector containing the EF1as-mCherry gene. The validation experiments were performed with LVs containing the EF1as-mCherry or EF1as-mAmetrine gene. 5′LTR, 5′ long terminal repeat; Ψ, psi packaging signal; RRE, Rev response element; cPPT, central polypurine tract; PBS, primer binding site for DNA sequencing library preparation; hU6, human U6 promoter; hPGK, human phosphoglycerate kinase promoter; hEF1a, human elongation factor 1a promoter; hEF1as, human elongation factor 1a short promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element; 3′LTR (SIN), 3′ long terminal repeat (self-inactivating); FC, fold change; PBs, plasmablasts.

    Article Snippet: CD43 – B cells were enriched from the spleen or lymph nodes of mice by immunomagnetic depletion of non-B cells using CD43 (Ly-48) MicroBeads (Miltenyi Biotec).

    Techniques: Sequencing, Infection, Cell Culture, Amplification, CRISPR, Cell Analysis, Virus, In Vivo, Clone Assay, Plasmid Preparation, Biomarker Discovery, Binding Assay, DNA Sequencing